Ascendis Pharma A/S is part of the healthcare sector and is in the biotechnology industry. The company CEO is Jan Moller Mikkelsen. Ascendis Pharma A/S is a biotechnology company that applies its TransCon technology to develop a pipeline of prodrug therapies with profiles that address markets with unmet medical needs.
Previous Intraday Performance:
The ASND shares had a previous change of 0.53% which opened at 117.20 and closed at 116.82. It moved to an intraday high of 119.08 and a low of 115.77.
Over the last five trading days, ASND shares returned 1.84% and in the past 30 trading days it returned -3.13%. Over three months, it changed 56.34%. In one year it has changed 86.88% and within that year its 52-week high was 131.76 and its 52-week low was 53.21. ASND stock is 119.57% above its 52 Week Low.
Our calculations result in a 200 day moving average of 75.09 and a 50 day moving average of 100.42. Right now, ASND stock is trading 55.58% above its 200 day moving average.
The company has a market cap of $5.5b with 46.8m shares outstanding and a float of 46.8m shares. Trading volume was 204,464 shares and has experienced an average volume of 593,092 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is good.
The last annual reported EPS for Ascendis Pharma A/S was -3.64 which ended on 31st of December 2018. Based on 3 analyst estimates, the consensus EPS for the next quarter is -0.78.
The next earnings report will be: 05-08-2019
The long-term trend of the EPS is a vital number as it helps understand the future potential of Ascendis Pharma A/S; it is usually expressed as a percentage and is then referred to as the EPS growth rate, which at this time is hard to estimate, but revenue growth has been 442.60% over the last twelve months.
Indicators Also to Watch:
Based on the latest filings, there is 122.90% of institutional ownership.
I calculated the beta to be 0.99
Based on last reported financials, the company’s return on equity is -54.71%, return on assets is -48.24%, price-to-sales is 448.79 and price-to-book is 17.35.
Company Score Card:
Results are out of six:
4 : Growth Expectations Result
6 : Financial Safety Result
0 : Past Performance Result
0 : Valuation Result
0 : Dividend Safety Result
2 : Overall Result